XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.3
License and Collaboration Revenue and Other Funding Agreements, Viatris License Agreement (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Sep. 30, 2025
USD ($)
Performanceobligation
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Performanceobligation
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Contract Assets and Unbilled Receivables [Abstract]              
Revenue recognized     $ 3,079 $ 3,867 $ 10,331 $ 6,690  
Viatris License Agreement [Member]              
Collaboration and License Agreement [Abstract]              
Non-refundable cash payment received   $ 35,000          
Maximum amount of payments receivable for development, regulatory and commercial milestones $ 130,000            
First milestone payments received $ 10,000            
Maximum percentage of tiered royalties receivable     20.00%   20.00%    
Number of distinct performance obligations | Performanceobligation     2   2    
Non-cancellation period of Constraint for Research and Development Revenue         120 days    
Contract Assets and Unbilled Receivables [Abstract]              
Balance as of beginning of period         $ 2,209 1,407  
Revenue recognized     $ 3,100 3,900 10,331 6,690  
Balance as of end of period     $ 1,364 $ 1,468 1,364 1,468  
Viatris License Agreement [Member] | License Transfer Fee [Member]              
Contract Assets and Unbilled Receivables [Abstract]              
Reclassification to Accounts receivable related to costs billed under the Viatris License Agreement         (11,176) $ (6,629)  
Viatris License Agreement [Member] | Sales Milestones [Member]              
Collaboration and License Agreement [Abstract]              
Milestone payment requirements attributed to the FDA's approval             $ 10,000
Contract Assets and Unbilled Receivables [Abstract]              
Revenue recognized         $ 0